target,target_id,target_uniprot,target_species,ligand,ligand_id,ligand_species,ligand_pubchem_cid,smiles,inchi,inchikey,type,action,action_comment,endogenous,primary_target,concentration_range,affinity_parameter,affinity_high,affinity_median,affinity_low,original_affinity_units,original_affinity_low_nm,original_affinity_median_nm,original_affinity_high_nm,original_affinity_relation,assay_description,receptor_site,ligand_context,pubmed_id pyruvate kinase M1/2,3006,P14618,Human,DMAMCL,9936,,133081974,C[NH+](C[C@@H]1C(=O)O[C@H]2[C@H]1CCC(=C1[C@@H]2[C@](C)(O)CC1)C)C,"InChI=1S/C17H27NO3/c1-10-5-6-12-13(9-18(3)4)16(19)21-15(12)14-11(10)7-8-17(14,2)20/h12-15,20H,5-9H2,1-4H3/p+1/t12-,13-,14-,15-,17+/m0/s1",ZPBIJIIQXPRJSS-WNZSCWOMSA-O,Activator,Activation,,,yes,,,,,,,,,,=,Direct target binding has been shown by binding of a biotinylated version of the parent molecule MCL to recombinant hPKM2 in vitro.,,,29641204, pyruvate kinase M1/2,3006,P14618,Human,mitapivat,10473,,59634741,O=C(c1ccc(cc1)NS(=O)(=O)c1cccc2c1nccc2)N1CCN(CC1)CC1CC1,"InChI=1S/C24H26N4O3S/c29-24(28-15-13-27(14-16-28)17-18-6-7-18)20-8-10-21(11-9-20)26-32(30,31)22-5-1-3-19-4-2-12-25-23(19)22/h1-5,8-12,18,26H,6-7,13-17H2",XAYGBKHKBBXDAK-UHFFFAOYSA-N,Allosteric modulator,Activation,,,,,pEC50,,7.0,,EC50,,100.0,,<,Activation of the PKM2 isoform.,,,, pyruvate kinase M1/2,3006,P14618,Human,compound 1 [PMID: 31465224],10493,,139593556,CNC(=O)CCc1nn(c(c1)c1ccc(cc1)c1ccc(cc1)C(F)(F)F)c1ccc(cc1)NC(=O)C#C,"InChI=1S/C29H23F3N4O2/c1-3-27(37)34-23-12-15-25(16-13-23)36-26(18-24(35-36)14-17-28(38)33-2)21-6-4-19(5-7-21)20-8-10-22(11-9-20)29(30,31)32/h1,4-13,15-16,18H,14,17H2,2H3,(H,33,38)(H,34,37)",UOGAVVINOTWELT-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pIC50,,6.6,,IC50,,250.0,,=,Measuring inhibition of pyruvate kinase activity in PC-9 cells treated with compound 1.,,,31465224, pyruvate kinase M1/2,3006,P14618,Human,TEPP-46,10555,,44246499,Nc1cccc(c1)Cn1ncc2c(c1=O)n(C)c1c2sc(c1)S(=O)C,"InChI=1S/C17H16N4O2S2/c1-20-13-7-14(25(2)23)24-16(13)12-8-19-21(17(22)15(12)20)9-10-4-3-5-11(18)6-10/h3-8H,9,18H2,1-2H3",ZWKJWVSEDISQIS-UHFFFAOYSA-N,Activator,Activation,,,,,,,,,,,,,=,,,,20451379, pyruvate kinase M1/2,3006,P14618,Human,DASA-58,10556,,44543605,Nc1cccc(c1)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc2c(c1)OCCO2,"InChI=1S/C19H23N3O6S2/c20-15-3-1-4-16(13-15)29(23,24)21-7-2-8-22(10-9-21)30(25,26)17-5-6-18-19(14-17)28-12-11-27-18/h1,3-6,13-14H,2,7-12,20H2",GMHIOMMKSMSRLY-UHFFFAOYSA-N,Activator,Activation,,,,,,,,,,,,,=,,,,21958545, pyruvate kinase M1/2,3006,P14618,Human,compound 16 [PMID: 31977207],10650,,145996537,CN(CC1C(=O)O[C@H]2[C@H]1CC/C(=C\CC[C@@]1([C@H]2O1)C)/C(=O)OCCOCCOC(=O)/C/1=C/CC[C@@]2(C)O[C@H]2[C@@H]2[C@@H](CC1)[C@H](CN(C)C)C(=O)O2)C,"InChI=1S/C38H56N2O11/c1-37-15-7-9-23(11-13-25-27(21-39(3)4)35(43)48-29(25)31(37)50-37)33(41)46-19-17-45-18-20-47-34(42)24-10-8-16-38(2)32(51-38)30-26(14-12-24)28(22-40(5)6)36(44)49-30/h9-10,25-32H,7-8,11-22H2,1-6H3/b23-9+,24-10+/t25-,26-,27-,28?,29-,30-,31-,32-,37+,38+/m0/s1",ZNXWRMSQZDHKCM-SBRQVZBJSA-N,Activator,Activation,,,,,pEC50,,7.82,,EC50,,15.0,,~,"Activation of PKM2 kinase activity (promotion of high kinase activity PKM2 tertramer formation) in vitro, by compound 5; described as AC50 in the reference,",,,31977207, pyruvate kinase M1/2,3006,P14618,Human,compound 24 [PMID: 36723914],12399,,167993641,C(c1ccccc1)N1C[C@@H](CC1)C(=O)N(CC1CCN(CC1)CC)c1ccc(cc1)[As](O)O,"InChI=1S/C26H36AsN3O3/c1-2-28-15-12-22(13-16-28)19-30(25-10-8-24(9-11-25)27(32)33)26(31)23-14-17-29(20-23)18-21-6-4-3-5-7-21/h3-11,22-23,32-33H,2,12-20H2,1H3/t23-/m1/s1",LXEHZSWUYHSECE-HSZRJFAPSA-N,Allosteric modulator,Inhibition,,,,,pIC50,,6.91,,IC50,,122.0,,=,Inhibition of PKM2 enzymatic activity,,,36723914,